• I. Siddique, S.P. Curran, A. Ghayur, L. Liu, C.J. Holmes, C.M. Hoff, A.S. Gangji, K.S. Brimble and P. Margetts (2013).  Gremlin causes peritoneal injury. Canadian Society of Nephrology Annual Meeting.

• J.K. Leypoldt, C. Hoff and C.J. Holmes (2012).  Peritoneal dialysis solutions containing low polydispersity glucose polymers as osmotic agents achieve higher ultrafiltration than 7.5% Icodextrin without an increase in carbohydrate absorption: validation in a rabbit model.  2012 American Society of Nephrology Proceedings. 

• Wang, L. Skoufos, J. Svatek, L. Lin and C.J. Holmes (2012). Identification of peptidoglycan, a non-endotoxin pyrogen in API using a peripheral blood mononuclear/IL-6 assay (PBMC/IL6) as an investigative tool – a case study.  Parenteral Drug Association Pharmaceutical Microbiology Meeting.

• R. Wang, L. Skoufos, J. Svatek, L. Lin and C.J. Holmes (2012). Optimization of a monocyte activation test used for detection of non-endotoxin pyrogen contaminants in parenteral drug products.  Parenteral Drug Association Annual Meeting.

• A. Bernardino, W. Kubey, W. Han, P. Straka, M. Muller, C.J. Holmes (2011).  Generation of infusible quality dialysate through a new hemodialysis device.  2011 American Society of Nephrology Proceedings.

• A. Akonur, C.J. Holmes and J.K. Leypoldt (2011).  Differences in peritoneal residual volume (VR) induce variability of ultrafiltration with icodextrin.  2011 EUROPD Book of Abstracts P-17.

• A. Akonur, M. Galach, J. Waniewski, C.J. Holmes and J.K. Leypoldt (2011).  Optimization of molecular weight (MW) for monodisperse glucose polymers (GPs) providing improved ultrafiltration (UF) without additional caloric load: a theoretical comparison with icodextrin.  2011 EUROPD Book of Abstracts P-16.

• C.M. Hoff, D. Piscopo, S. Carr, J.M. Svatek, C.J. Holmes, R. Wang and J.K. Leypoldt (2011).  Evaluation of glucose and icodextrin based bimodal peritoneal dialysis solutions in a rabbit model.  2011 EUROPD Book of Abstracts P-1.

• J.K. Leypoldt, D. Piscopo, S.N. Carr, J. Svatek, C.J. Holmes and C. Hoff (2011).  Effect of molecular weight on the ultrafiltration (UF) efficiency of glucose polymers with low polydispersity.  2011 EUROPD Book of Abstracts P-15.

• B.L. Riser, F.C. Barreto, R. Rezg, P.W. Valaitis, C.S. Cook, J.A. White, J.H. Glass, J. Maizel, L. Louver, T.B. Drueke, C.J. Holmes and Z.A. Massy (2010).  Sodium pyrophosphate delivered in a peritoneal dialysis solution prevents vascular calcification in a mouse model of hypercholesterolemia, uremia and atherosclerosis.  2010 EDTA Proceedings.

• A. Akonur, C.J. Holmes and J.K. Leypoldt (2008).  Icodextrin allows reduction of glucose absorption during short dwells in automated peritoneal dialysis (APD).  Peritoneal Dialysis International 28(suppl 4):113.

• A. Akonur, C.J. Holmes and J.K. Leypoldt (2008).  Ultrafiltration (UF) efficiency during automated peritoneal dialysis using glucose based solutions. Peritoneal Dialysis International 28(suppl 1):S29.

• C. Hoff, D. Piscopo, S. Carr, J. Svatek, B. Feldman, N. Arora, C.J. Holmes, J.K. Leypoldt (2007).  A rabbit model for the study of Icodextrin-based peritoneal dialysis solution.  ASN 2007 abstract.

• R. Wang, L. Skoufos, C.J. Holmes (2007).  Blood glucose measurements for diabetic peritoneal dialysis patients.  8^th EUROPD meeting: Book of abstracts, p12.

• J.P. Margetts, P. Patel, C.M. Hoff, C.J. Holmes, J.C. Rodriguez (2006). Effects of platelet derived growth factor on the peritoneum.  Peritoneal Dialysis International 26 (suppl 2); S17.

• C.M. Hoff, D. Piscopo, J.M. Svatek and C.J. Holmes (2006). Local and systemic effects of peritoneal dialysis solution on uremic rats.  Peritoneal Dialysis International 26 (suppl 2); S15.

• K. Pawlaczyk, C.J. Holmes, M. Kulan-Pawlaczyk, S. Czekalski, A. Breborowicz and B. Lindholm (2006).  Spontaneous peritonitis in rats undergoing chronic peritoneal dialysis.  Peritoneal Dialysis International 26 (suppl 2); S19.

• Y. Maruyama, L. Nordfors, P. Stenvinckel, O. Heimburger, P. Barany, R. Pecoits-Filho, J. Axelsson, C.M. Hoff, C.J. Holmes, M. Schalling and B. Lindholm (2004).  Interleukin 1 gene cluster polymorphisms with nutritional status and inflammation in patients with end stage renal disease.   Journal of the American Society of Nephrology 15; 150A.

• C.M. Hoff, D. Piscopo, J. Svatek, C.J. Holmes, K. Honda and P.J. Margetts (2004).  Pilot study to establish an experimental animal model of EPS: potential contributing factors.  Peritoneal Dialysis International 24(2):S4.

• Y. Maruyama, L. Nordfors, P. Stenvinckel, O. Heimburger, J. Axelsson, R. Pecoits-Filho, P. Barany, C.M. Hoff, C.J. Holmes and B. Lindholm (2004).  Tumor necrosis factor a-308 G/A promoter polymorphism is associated with hypoalbuminemia in patients with end stage renal disease.   EDTA proceedings.

• K. Wang, H. Honda, A. R. Qureshi, R. Pecoits-Filho, J. Axelsson, L. Nordfors, M. Schalling, C.M. Hoff, C.J. Holmes, O. Heimburger, P. Stenvinckel and B. Lindholm (2004). Association of the Matrix Gla Protein polymorphism with carotid intima-media area and left ventricular hypertrophy in end stage renal disease patients.  EDTA proceedings.

• K. Wang, H. Honda, A. R. Qureshi, R. Pecoits-Filho, J. Axelsson, L. Nordfors, M. Schalling, C.M. Hoff, C.J. Holmes, O. Heimburger, P. Stenvinckel and B. Lindholm (2004). The Matrix Gla Protein genotype is associated with clinical outcome in end stage renal disease patients.  EDTA proceedings.

• M. Numata, M. Nakayama, T. Hosoya, C.M. Hoff, C.J. Holmes, M. Schalling, L. Nordfors and B. Lindholm (2003).  A single nucleotide polymorphism in the RAGE –429 T/C genotype may be related to encapsulating peritoneal sclerosis in Japanese peritoneal dialysis patients.  Journal of the American Society of Nephrology14:214A.

• W. Kubey, P. Straka, C.J. Holmes and B. Connell (2003).  A new PD connection system that reduces the risk of touch contamination: validation of the walkaway mode component for APD.  Journal of the American Society of Nephrology14:485A. 

• P.J. Margetts, LM Liu, B. Rochwerg, C.M. Hoff and C.J. Holmes (2003).  Early fibrogenic events after transient overexpression of transforming growth factor beta: evidence for epithelial mesenchymal transition.  Journal of the American Society of Nephrology14:332A.

• P. Stenvinckel, A. Marchlewska, R. Pecoits-Filho, O. Heimburger, C. Hoff, C.J. Holmes, J. Axelsson, P. Barany, B. Lindholm and L. Nordfors (2003).  Plasma adiponectin and its relations to albuminuria, type of diabetes, body composition, inflammation and genetic variations in the gene encoding adiponectin in ESRD.  Journal of the American Society of Nephrology14:531A. 

• C.M. Hoff, D. Piscopo, J.M. Svatek, J.L. Barnes, B.L. Riser and C.J. Holmes (2003).  Combined renoprotective effect of captopril and pravastatin in STZ diabetic rats.  Journal of the American Society of Nephrology 14:132A.

• R. Selgas, A. Puig-Corver, M. Auxiliadora Bajo, J.A. Sanchez-Tomero, V. Alvarez, G. del Paso, P. Sanchez-Mateos, C.J. Holmes, D. Faict and A. Corbi (2003).  Peritoneal Dialysis solutions inhibit dendritic cell maturation: effect of lactate.  Nephrology, Dialysis and Transplantation 18(4): 766.

• W. Kubey, P. Straka, C.J. Holmes, B. Connell (2003).  A new PD disconnection system that prevents touch contamination during disconnection: Validation of the integrity of the self-sealing septum.  Nephrology, Dialysis and Transplantation 18(4):774.

• P.J. Margetts, T. Galt, L. Yu, C.M. Hoff, C.J. Holmes  and J. Gauldie (2002).  Adenovirus mediated gene transfer of transforming growth factor b3 to the rat peritoneum leads to transient ultrafiltration dysfunction.  Journal of the American Society of Nephrology 13: 40A.

• P.J. Margetts, L. Yu, C.M. Hoff, C.J. Holmes  and J. Gauldie (2002).  Combined ant-angiogenic and antifibrotic therapy in a rodent model of peritoneal membrane failure.  Peritoneal Dialysis International 22(1): 101.

• R. Selgas, A. Puig-Kroger, M.A. Bajo, J.A. Sanchez-Tomero, V. Alvarez, G. del Peso, P. Sanchez-Mateos, C.J. Holmes, D. Faict, M. Lopez-Cabrera, and A.L. Corbi (2002).  Peritoneal dialysis solutions inhibit dendritic cell maturation: effect of lactate.  Peritoneal Dialysis International 22(1):107.

• R. Selgas, A. Puig-Kroger, M.A. Bajo, J.A. Sanchez-Tomero, V. Alvarez, G. del Peso, P. Sanchez-Mateos, C.J. Holmes, D. Faict, M. Lopez-Cabrera, and A.L. Corbi (2002).  The effect of peritonitis on peritoneal permeability during chronic peritoneal dialysis.  Peritoneal Dialysis International 22( suppl 1):S15.

• D.J. Millar, P.J. Thornalley, C.J. Holmes, A. Dawnay (2001).  In vitro kinetics of AGE formation with PD fluid resembles that of glucose degradation products (GDPs) rather than glucose. Journal of the American Society of Nephrology 12:434A.

• K. Pawlaczyk , M. Kuzlan-Pawlaczyk, O. Heimburger, J. Bergstrom, C.J. Holmes, A. Breborowicz and B. Lindholm (2001).  The effect of peritonitis on peritoneal permeability during chronic peritoneal dialysis.  Peritoneal Dialysis International 21(suppl 2):S116.

• M. Kuzlan-Pawlaczyk, K. Pawlaczyk, B. Anderstam, J. Bergstrom, C.J. Holmes, A. Breborowicz and B. Lindholm (2001).  Inflammatory reaction during spontaneous peritonitis in rats undergoing chronic peritoneal dialysis.  Peritoneal Dialysis International 21(suppl 2):S114.

• L. Cooker, P. Luneburg, C.J. Holmes and N. Topley on behalf of the lactate/bicarbonate study group (2001).  Dialysate levels of IL-6 and VEGF decrease in patients using bicarbonate/lactate-based peritoneal dialysis solutions.  Peritoneal Dialysis International 21(suppl 2):S18.

• M.S. Park, J.K. Kim, C.J. Holmes, W.F. Weiss (2001). Peritoneal AGE accumulation after long-term use of low GDP solutions.  Peritoneal Dialysis International 21(suppl 1):S17.

• D. J. Millar, G. W. Taylor, P. J. Thornalley, C. J. Holmes, A. Dawnay (2000).  Comparison of in vitro protein modification with AGE precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using mass spectrometry. Journal of the American Society of Nephrology 11:213A.

• L. Cooker, D. Faict, C. J. Holmes on behalf of the AGE PD Solution Study Group.  Will the new generation of peritoneal dialysis solutions lead to reduced peritoneal membrane age formation?  AGE Symposium, Klinikum der Freidrich-Schiller-Universität Jena, Jena, Germany.

• W. Kubey, P. Straka, C.J. Holmes (2000).  A neutral pH Bicarbonate/Lactate-based peritoneal dialysis solution does not result in increased bacterial growth using an in vitro equilibration system. Peritoneal Dialysis International 20(1):132.

• N. Topley, R. Krediet, S. Jones, D. Faict, A. Tranaeus, C.J. Holmes (2000).  Peritoneal CA125, hyaluronan, TGFb1 and pro-collagen I peptide in a randomized, controlled study of bicarbonate/lactate based CAPD solution. Peritoneal Dialysis International 20(1):150.

• M.S. Park, J.H. Cha, S.I. Kim, C.J. Holmes, H.B. Lee (2000).  The effect of long term use of bicarbonate containing neutral dialysis solutions on peritoneal structure and function. Peritoneal Dialysis International 20(Suppl 1):S12.

• Dawnay, M. Argirova, D.J. Millar, C.J. Holmes, P.J. Thornalley (1999).  Reduction of dicarbonyl compounds in a novel peritoneal dialysis solution.  1999 U.K. Renal Association Abstract.

• N. Topley, R. Krediet, S. Jones, D. Faict, A. Tranaeus, C.J. Holmes (1999).  Peritoneal CA125, hyaluronan, TGFb1 and pro-collagen I peptide in a randomized, controlled study of bicarbonate/lactate based CAPD solution. Journal of the American Society of Nephrology, 10:230A.

• Dawnay, M. Argirova, D.J. Millar, C.J. Holmes, P.J. Thornalley (1999).  Reduction of dicarbonyl compounds in a novel peritoneal dialysis solution. Journal of the American Society of Nephrology, 10; 312A.

• D.J. Millar, C. Holmes, D. Faict,  A. Dawnay (1999).  Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation.  Kidney International 55(6); 2559.

• J.D. Williams, C.J. Holmes, S. Jones, R. Mackenzie, G.A. Coles, D. Faict and N. Topley (1999).  Improved ex vivo peritoneal macrophage TNFa secretion following long term in vivo exposure to bicarbonate/lactate dialysis fluid.  Proceedings of XVth International Congress of Nephrology; 441.

• J.D. Williams, S. Jones, C.J. Holmes, R. Mackenzie, G.A. Coles, D. Faict and N. Topley (1999).  Decreased pro-collagen I and TGF b1 levels in peritoneal dialysis effluent following exposure to bicarbonate/lactate buffered peritoneal dialysis fluid. Proceedings of XVth International Congress of Nephrology; 443.

• J. Laiuppa, E. Lee, M. DeLeo, W. Kubey, P. Straka, C.J. Holmes (1999). Evaluation of peritoneal dialysis catheters with a heparin coating and porous silicone cuff.  ASAIO Journal 45(2); 192.

• L.A. Cooker, C.G. Choo, P. Luneburg, J. Lamella and C.J. Holmes (1999).  In vitro biocompatibility of ExtranealÔ.  Peritoneal Dialysis International 19(Suppl 1):S77.

• E. Lee, J. Laiuppa, M. DeLeo, J. Gass and C.J. Holmes (1999).  Effects of pore size, void volume and pore connectivity on tissue response to porous silicone implants.  Society of Biomaterials.

• J. Laiuppa, W. Kubey, P. Straka, E. Lee, M DeLeo and C.J. Holmes (1999).  Hyaluronic acid coated peritoneal catheters reduce bacterial adhesion and protein deposition.  Peritoneal Dialysis International 19(Suppl 1):S41.

• N. Topley, S. Jones, C.J. Holmes, R. Mackenzie, G.A. Coles, D. Faict and J.D. Williams (1998).  In vivo exposure to Bicarbonate/lactate-buffered peritoneal dialysis fluid decreases pro-collagen I and transforming growth factor-b1 levels in peritoneal dialysis effluent. Journal of the American Society of Nephrology 9:290A.

• J.D. Williams, C.J. Holmes, S. Jones, R. Mackenzie, G.A. Coles, D. Faict and N. Topley (1998).  Long term in vivo exposure to Bicarbonate/Lactate dialysis fluid improves ex vivo peritoneal macrophage TNF secretion. Journal of the American Society of Nephrology 9:292A.

• S. Jones, J.D. Williams, C.J. Holmes, R. Mackenzie, G.A. Coles, D. Faict and N. Topley (1998).  Bicarbonate/lactate-buffered peritoneal dialysis fluid decreases pro-collagen I and transforming growth factor-b1 levels in peritoneal dialysis effluent. Peritoneal Dialysis International 18(Suppl 2):S83.

• J.D. Williams, C.J. Holmes, S. Jones, R. Mackenzie, G.A. Coles, D. Faict and N. Topley (1998).  Long term in vivo exposure to Bicarbonate/Lactate dialysis fluid improves ex vivo peritoneal macrophage function. Peritoneal Dialysis International 18(Suppl 2):S83.

• K. Wieczorowska-Tobis, K. Pawlaczyk, M. Kuzlan-Pawlaczyk, A. Polubinska, J. Wisniewska, C.J. Holmes and A. Breborowicz (1988).  Bicarbonate-lactate (Bic-Lac) solution with neutral pH improves peritoneal host defense in vivo.  Peritoneal Dialysis International 18(Suppl 2):S34.

• D.J. Millar, C.J. Holmes, D. Faict, A. Dawnay (1998).  Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation.  Peritoneal Dialysis International 18 (Suppl 1):S74 (Oral presentation).

• C.J. Holmes, S. Jones, R. MacKenzie, G.A. Coles, J.D. Williams, A. Tranaeus and N. Topley (1997).  Bicarbonate/Lactate-buffered (TBL) peritoneal dialysis fluid (PDF) decreases pro-collagen I levels in peritoneal dialysis effluent (PDE). Journal of the American Society of Nephrology, 8:264A.

• R. MacKenzie, C.J. Holmes, J.D. Williams, A. Moseley, R. Argyle, G.A. Coles, D. Faict, A. Tranaeus, and N. Topley (1997). Acute in vivo exposure to bicarbonate/lactate and bicarbonate buffered peritoneal dialysis fluids (PDF) improve lipopolysaccharide driven peritoneal macrophage (PM) TNF secretion.  Nephrology, 3(1):S402.

• N. Topley, R. MacKenzie, J.D. Williams, G.A. Coles, A. Tranaeus, D. Faict, A. Moseley, R. Argyle, S. Jones and C.J. Holmes (1997). In vivo exposure to bicarbonate/lactate-buffered peritoneal dialysis fluids (PDF) improves ex vivo peritoneal macrophage (PM) function compared to bicarbonate (TB) and lactate-buffered PDF.  Nephrology, 3(1):S408.

• Degremont, C.J. Holmes, W. Kubey, P. Straka, N.K. Man (1997).  Efficacy of disinfectants versus a procedure including cleaning and disinfection steps on biofilm in dialysis machines. Nephrology, 3(1):S532.

• L. Cooker, J. Witowski, N. Topley and C.J. Holmes (1997).  Expression of messenger RNA for advanced glycation endproduct receptor (RAGE) in human mesothelial cells. Nephrology, 3(1): S62 (Oral presentation – best six posters).

• W. Kubey, P. Straka and C.J. Holmes (1997). Effective Titanium Adapter Disinfection for PD Transfer Set Change Procedure.  Peritoneal Dialysis International, 17(1):S75.

• N. Topley, R. MacKenzie, J.D. Williams, A. Moseley, R. Argyle, G.A. Coles, D. Faict, A. Tranaeus and C.J. Holmes (1997).  Acute in vivo exposure to bicarbonate/lactate (TBL) and bicarbonate (TB) buffered peritoneal dialysis fluids (PDF) improves LPS driven peritoneal macrophage (PMØ) TNF secretion.  Peritoneal Dialysis International (oral presentation), 17(1):S39.

• R. Mackenzie, J.D. Williams, A. Moseley, R. Argyle, G.A. Coles, C. J. Holmes, D. Faict, A. Tranaeus, D. De Groot and N. Topley (1996).  In vivo exposure to bicarbonate/lactate (TBL) and bicarbonate (TB) buffered peritoneal dialysis fluids (PDF) improves ex vivo peritoneal macrophage (PM) function.  Journal of the American Society of Nephrology, 7(9): 1431.

• Douvdevani, C.J.  Holmes,  C. Chaimovitz (1996).  The effect of bicarbonate-based peritoneal dialysis solution (PDS) on TNFa production by peritoneal macrophages (PM). Journal of the American Society of Nephrology, 7(9):1427.

• S. Sundaram, M. Cendoroglo, L.A. Cooker, C.J. Holmes, D. Faict, and B.J.G. Pereira (1996).  The effect of bicarbonate-lactate buffered peritoneal dialysis (PD) fluids on neutrophil phagocytosis, oxidative burst and enzyme release. Journal of the American Society of Nephrology, 7(9):1434.

• M. Cendoroglo, S. Sundaram, L.A. Cooker, C.J. Holmes, D. Faict and B.J.G. Pereira (1996).  The effect of bicarbonate-lactate buffered peritoneal dialysis (PD) fluids on cytokine production by peripheral blood mononuclear cells (PBMC). Journal of the American Society of Nephrology, 7(9):1425.

• M. Cendoroglo, S. Sundaram, L.A. Cooker, C.J. Holmes, and B.J.G. Pereira (1996).  Effect of glucose concentration, osmolality and sterilization process of peritoneal dialysis (PD) solutions on cytokine production by peripheral blood mononuclear cells (PBMC). Journal of the American Society of Nephrology, 7(9):1426.

• S. Sundaram, M. Cendoroglo, L.A. Cooker, C.J. Holmes, and B.J.G. Pereira (1996).   Biocompatibility (BC) of peritoneal dialysis (PD) fluids:  Role of glucose concentration, osmolality and sterilization process on neutrophil function. Journal of the American Society of Nephrology, 7(9):1434.

• M. Cendoroglo, S. Sundaram, L.A. Cooker, C.J. Holmes, A.J. King, B.J.G. Pereira (1996).  Neutrophil dysfunction with peritoneal dialysis (PD) fluids: A possible role for apoptosis. Journal of the American Society of Nephrology, 7(9):1426.

• Degremont, C.J. Holmes,  W. Kubey, P. Straka & N.K. Man (1996).  Efficacy of chemical disinfectants used alone vs combination of decalcification and autoclavage of biofilm developed in dialysis machines.  EDTA abstract, p 278.

• L. Cooker, P. Luneburg, D. Faict and C.J. Holmes (1996).  Reduced inhibition of cell growth due to glucose degradation products (GDPs) with bicarbonate-based PD solutions.  2nd European Peritoneal Dialysis Meeting, p 27.

• C.J. Holmes,  D. Kaur, M. Hallett, D. Faict, J.D. Williams & N. Topley (1995).  In vitro effect of bicarbonate buffered peritoneal dialysis solutions on human neutrophil cytoplasmic pH.  Proceedings of the 6th Asian-Pacific Congress of Nephrology, pp 36 (Oral presentation).

• C.J. Holmes, G. Hickey, P. Cipolla and W. Kubey (1995).  Bacterial proliferation in peritoneal dialysis effluent after exposure to acidic dialysis solution – Implications for neutral pH formulations.  Blood Purification 13 (Suppl 1):23.

• Faller for the Mupirocin Study Group {includes C.J. Holmes} (1995).  The effect of intranasal mupirocin on CAPD exit site infection (ESI).  Peritoneal Dialysis International 15(4):S51.

• C.J. Holmes, W. Kubey, P. Luneburg, P. Straka and K. Pu (1995).  Flushing of Twinbag/Ultrabag (TB/UB) systems can be performed either before or after effluent drain: a bacterial removal efficiency study.  Peritoneal Dialysis International 15(Suppl 1):19.

• C.J. Holmes, W. Kubey, P. Luneburg, S. Ericson and J. Brown (1995).  Longitudinal in vitro antimicrobial evaluation of two silver polymer surface treatments for peritoneal dialysis catheters.  Peritoneal Dialysis International 15(Suppl 1):55.

• C.J. Holmes, N. Topley, D. Kaur, M.M. Petersen, D. Faict and J.D. Williams (1994).  A biocompatibility comparison of bicarbonate versus bicarbonate-lactate based solutions for peritoneal dialysis (PD).  Journal of American Society of Nephrology 5(3):453.

• G. Coles for the Mupirocin Study Group {includes C.J. Holmes} (1994).  The effect of intranasal mupirocin on CAPD exit site infection (ESI).  Journal of American Society of Nephrology 5(3):439.

• S. L. Lewis, S. G. Kutvirt, C.J. Holmes (1994) Calcium metabolism in blood and peritoneal dialysis effluent lymphocytes.  Peritoneal Dialysis International 14(1):S15.

• R.C. Evans, J. Ebben, D. Luhring, P. Keshaviah and C.J. Holmes (1993).  Comparison of plasma cytokines and inhibitory proteins in patients using high and low flux modified cellulosic membranes.  XIIth International Congress of Nephrology, p365.

• C.J. Holmes, W. Kubey, F. Aono, and M. Vachula (1992).  In vitro effect of an amino acid-based peritoneal dialysis fluid on human receptor leukocyte function and receptor expression.  Journal of the American Society of Nephrology 3(3):412.

• C.J. Holmes, R.C. Evans and L. Henderson. (1992). Role of Plasma in the transfer of cytokine inducing substances (CIS) across cellulosic membranes.  Blood Purification 10:96.

• B.J. Wood, K.S. Morgan, D.G. Erickson, C.J. Holmes and S.L. Lewis (1992).  Relationship between persistent peritonitis and altered immune status. Peritoneal Dialysis International 12(2):21.

• S.L. Lewis, C.L. Cooper, P.N. Bonner, and C.J. Holmes (1992).  Prospective analysis of blood and peritoneal lymphocytes from CAPD patients.  Peritoneal Dialysis International 12(2):21.

• S.L. Lewis, S.G. Kutvirt and C.J. Holmes (1992).  Interleukin 2 production by peritoneal and peripheral lymphocytes from CAPD patients.  Peritoneal Dialysis International 12(1):137

• M. Vachula, F. Aono, W. Kubey and C.J. Holmes (1991).  Effect of peritoneal dialysis fluid on mononuclear cell surface receptor expression.  Journal of the American Society of Nephrology 1(4):361.

• R.C. Evans, W.Y. Kubey, C.J. Holmes, C. DeVos and V. Joyeux (1990).   In vivo effects of two high flux hemodialysis membranes on plasma cytokine levels.   Journal of the American Society of Nephrology 1(4):361.

• N. Kastler.  R. Evans, C.J. Homes, A. Collins and P. Keshaviah (1990).  Influence of acetate-based dialysis on plasma cytokine levels.  XIth International Congress of Nephrology, p242A.

• W. Kubey, P. Luneburg and C.J. Holmes (1990).  Comparison of the ability of povidone iodine and 70% isopropyl alcohol to disinfect the medication ports of CAPD solution containers.  Proceedings of Vth Congress of the International Society for Peritoneal Dialysis, p88.

• C.J. Holmes and W. Kubey (1990).  The relationship between PD effluent absorbance of ultraviolet (UV) light and the microbiocidal effectiveness of mercury vapor and Xenon based UV disinfection systems for CAPD.  Proceedings of Vth Congress of the International Society for Peritoneal Dialysis, p29 (Oral Presentation).

• S.L. Lewis, P.J. Norris and C.J. Holmes (1990).  Phenotypic characterization of monocytes/macrophages from CAPD patients.  Proceedings of American Society for Artificial Internal Organs, p. 78.

• W. Kubey, P. Luneburg and C.J. Homes (1990).  Microbiocidal effectiveness of Xenon-based UV for CAPD exchange procedure.  Peritoneal Dialysis International 10(1), #96.

• S.L. Lewis, P.J. Norris and C.J. Holmes (1990).  Phenotypic characterization of lymphocytes from peritoneal dialysis effluents of CAPD patients.  Peritoneal Dialysis International 10(1), #104.

• C.J. Holmes, R. Evans, D. Ross and P. Frankamp (1989).  Plasma interleukin-1 and tumor necrosis factor levels during high flux hemodialysis with cellulose triacetate membranes.  Proceedings of American Society of Nephrology, p. 113A.

• R. Evans, W. Kubey, P. Luneburg and C.J. Holmes (1989).  Pseudomonas aeruginosa derived cytokine-inducing material transport across high flux hemodialysis membranes.  Proceedings of American Society of Nephrology, p. 107A.

• W. Kubey, P. Luneburg and C.J. Holmes (1989).  Microbiocidal effectiveness of a Xenon-based ultraviolet light source for CAPD connections.  Proceedings of American Society of Nephrology, p. 143A.

• C.J. Holmes, R.C. Evans, M. Salit and M.J. Lysaght (1989).  Transport of cytokine-inducing material across high flux hemodialyzers is microorganism dependent.  Proceedings of International Society of Blood Purification, p. 260 (Oral Presentation).

• C.J. Holmes, S. Lewis, R. Evans, W. Kubey, P. Luneburg and D. Mucha (1989).  Periodic elevation of complement activation products in peritoneal dialysis effluent.  Proceedings of American Society for Artificial Internal Organs, p. 78.

• R.C. Evans, C.J. Holmes, P.A. Luneberg and W. Kubey (1989). Factors influencing bacterial multiplication in CAPD effluent.  Peritoneal Dialysis International (9) Suppl 1:52.

• C.J. Holmes, J. Chapman and F. Aono (1989).  Longitudinal study of humoral immune factors in CAPD effluent.  Peritoneal Dialysis International (9) Suppl 1: 81.

• S. Lewis, C.J. Holmes and W. Kubey (1989).  Comparison of peritoneal white blood cell parameters from CAPD patients identified at high or low risk for peritonitis. Peritoneal Dialysis International (9) Suppl 1:103.

• T. Golper, D. Sewell, K. West, C.J. Holmes and W. Kubey (1989).  Comparison of laboratory methods for the isolation of microorganisms from peritoneal dialysate. Peritoneal Dialysis International (9) Suppl 1:69.

• J. Chapman, C.J. Holmes and F. Aono (1988).  Longitudinal study of humoral factors in CAPD effluent. Proceedings of American Society of Nephrology, p. 120A.

• C.J. Holmes, R. Evans and M. Salit (1988).  Endotoxin transport across high flux capillary fiber dialysis membranes – an in vitro study.  Proceedings of American Society of Nephrology, p. 101A.

• F. Aono, W. Lee, C.J. Holmes and J. Chapman (1988).  Complement and antibody activity in peritoneal effluent dialysis patients.  Federation Proceedings, p. A452.

• J. Chapman, F. Aono and C.J. Holmes (1987).  Immunologic assessment of CAPD effluent.  Proceedings of American Society of Nephrology, p. 97A.

• M. Salit, J.J. Chase, W. Kubey, C.J. Holmes and F.C. Pearson (1987).  Effect of Monophosphoryl Lipid A combined with Trehalose Dimycolate on host resistance to bacterial infection.  Proceedings of American Society for Microbiology, p. 24.

• R.C. Evans and C.J. Holmes (1987).  In vitro modeling of a biomaterial staphylococcal biofilm.  Peritoneal Dialysis Bulletin 6(4) Suppl: S6 (Oral Presentation).

• M. Salit, J.J. Chase, W. Kubey, C.J. Holmes, R. Kroes, F.C. Pearson, C. Lee and J. Sensibar (1987).  Partial characterization of peritoneal dialysis effluents by 2-dimensional electrophoresis.  Peritoneal Dialysis Bulletin 6(4) Suppl: S17.

• R.C. Evans and C.J. Holmes (1986).  In vitro modeling of biofilm development on medical grade plastics.  Proceedings of XIV International Congress of Microbiology, p. 304.

• J. Chase, W. Kubey, M. Dulek, C.J. Holmes, M. Salit, F. Pearson and J. Thomas (1986).  Effect of Monophosphoryl Lipid A on host resistance to bacterial infection.  Federation Proceedings, 45(3):333.

• C.J. Holmes, V. LaSpisa and J. Anderson (1986).  In vitro adherence of Staphylococcus epidermidis to peritoneal mesothelial cells.  Proceedings of American Society for Microbiology, p. 74.

• W. Kubey, J. Chase and C.J. Holmes (1986).  In vitro evaluation of the antimicrobial efficacy of trichloroisocyanuric acid in a urinary drainage bag.  Proceedings of American Society for Microbiology, p. 419.

• W. Kubey, J. Chase and C.J. Holmes (1986).  In vitro study of the antimicrobial efficacy of a silver oxide coated urinary drainage system catheter adapter.  Proceedings of American Society for Microbiology, p. 418.

• C.J. Holmes, R.K. Ausman, C.W. Walter and R.B. Kundsin (1979).    Potential hazards associated with the microbial contamination of in-line terminal filters during intravenous therapy.  Proceedings of American Society of Hospital Pharmacists Mid-year Clinical Meeting, p. 142.

• C.J. Holmes, R.K. Ausman, C.W. Walter and R.B. Kundsin (1979).  An improved central admixture program.  Proceedings of American Society of Hospital Pharmacists Mid-year Clinical Meeting, p. 142.

• C.J. Holmes and M.C. Allwood (1976).  Rubber closures: a possible route for microbial contamination of intravenous infusions.  Journal of Applied Bacteriology 41: xxiv (Oral Presentation).

• C.J. Holmes and M.C. Allwood (1976).  Rubber closures: a possible route for microbial contamination of intravenous infusions.  Journal of Applied Bacteriology 41: xxiv (Oral Presentation).

• D.B. Drucker and C.J. Holmes (1975).  Fatty acid profiles of Streptococci of Lancefield groups A,B,C,D,E,F,G,H,K,O,P and Q.  Proceedings of the Society for General Microbiology ii: 19-20.

• D.B. Drucker, C.J. Holmes, M.V. Stack, H. Donoghue, J.E. Taylor and M. Marshall (1975).  Comparison of two G.L.C. techniques for identifying Streptococci of several Lancefield groups.  Journal of Applied Bacteriology 39: viii-ix.

ACKNOWLEDGMENTS IN:                                                                                                                                                                                        

E.H. Elphick, L. Teece, J.A. Chess, J-Y Do, Y-L Kim, H. Bahl Lee, S.N. Davison, N. Topley, S.J. Davies and M. Lambie (2018).  Biocompatible solutions and long-term changes in peritoneal solute transport.  Clinical Journal of the American Society of Nephrology Vol 13 October https://doi.org/10.2215/CJN.02380218

L.M. Martis, M. Patel, J. Giertych, J. Mongoven, M. Taminne, M.A. Perrier, O. Mendoza, N. Goud, A. Costigan, C. Verger and W. Owen (2005).  Aseptic peritonitis secondary to peptidoglycan contamination of Pharmacopeia standard solution.  Lancet 365;588-594.

G.F.M. Strippoli, A. Tong, D. Johnson, F.P. Schena and J.C. Craig (2004).  Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials.  American Journal of Kidney Diseases 44(4); 591-603.

N.J. Ofsthun and J.K. Leypoldt (1995).  Ultrafiltration and backfiltration during hemodialysis.  Artificial Organs 19(11); 1143-61.

The Ad Hoc Advisory Committee on Peritonitis Management (1993).  Peritoneal dialysis related peritonitis treatments recommendations; 1993 update.  Peritoneal Dialysis International 13(1):14-28.